Could a lower dose of burosumab work just as well for XLH?
NCT ID NCT07183579
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
XLH is a rare genetic condition that causes low phosphate levels, leading to weak bones and pain. Burosumab is a standard treatment, but the best starting dose is still unclear. This study will review the medical records of 120 children across England to see if a lower dose (under 0.8 mg/kg) can still control phosphate levels effectively. The goal is to find the safest, most effective dose for each child.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- burosumab (Crysvita)
- What this could lead to
- If successful, this study could help doctors choose the lowest effective dose of burosumab for children with XLH, reducing unnecessary high-dose exposure while still controlling phosphate levels.
- What could go wrong
- This is an observational study that only looks back at existing medical records, so it cannot prove cause and effect. Results may vary across different clinics and may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED HYPOPHOSPHATEMIA (XLH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nottingham University Hospitals NHS Trust
RECRUITINGNottingham, NG7 2UH, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.